Avedro Broadens Cross-Link Product Line

Avedro Broadens Cross-Link Product Line
Corneal collagen cross-linking has been a vexing specialty for US-based companies trying to guide a product through a cautious FDA. But Massachusetts-based Avedro Inc., continues to establish a meaningful portfolio in the space through deals like the acquisition of Switzerland-based IROC Innocross AG.

Avedro acquired the assets of IROC Innocross, which was the first company to commercialize a cross-linking device for the treatment of keratoconus and other corneal pathologies, according to a release announcing the deal.

Avedro CEO David Muller says the deal makes Avedro

the only cross-linking company to address the entire market for corneal cross-linking procedures across all price points, allowing our seasoned distribution network to aggressively compete for and win the business of any ophthalmologist in the cross-linking space.”

First developed in Germany in the late 1990s, corneal cross-linking combines ultra-violet light and riboflavin eye drops to stabilize the cornea, according to the company. This limits the progression of keratoconus, a non-inflammatory eye condition that weakens the cornea.

At the April OIS@ASCRS, Muller participated in a short debate about whether cross-linking should be performed with a portion of the corneal epithelial off or on. Watch that exchange, as well as a panel discussion featuring venture capitalists, physicians and entrepreneurs as they review this opportunity in cross-linking, here.

Additionally, check back for an OIS Podcast featuring Muller coming soon.

SHARE THIS ARTICLE WITH YOUR COLLEAGUES:

RECOMMENDED FOR YOU

How Omega Ophthalmics Hopes to Redefine Use of the Capsular Bag with the Gemini Refractive Capsule

How Omega Ophthalmics Hopes to Redefine Use of the Capsular Bag with the Gemini Refractive Capsule

Glaukos' Bid for Avedro: What's Next

A Closer Look at Glaukos’ Bid for Avedro

OIS@ASRS Reporter's Notebook: Three Things Learned at OIS@ASRS About What Funders Want, Going Global, and AI

OIS@ASRS Reporter’s Notebook: Three Things Learned at OIS@ASRS About What Funders Want, Going Global, and AI

Recent Moves Show How Zeiss Is Positioning Itself for a New Era in Ophthalmology

Recent Moves Show How Zeiss Is Positioning Itself for a New Era in Ophthalmology

National Vision and Eye Health Surveillance System Gears Up for September Launch

National Vision and Eye Health Surveillance System Gears Up for September Launch

OIS@ASRS at the Ritz-Carlton Chicago: An In-depth Look at the Retina Space

OIS@ASRS at the Ritz-Carlton Chicago: An In-depth Look at the Retina Space

About The Author

Tom Salemi

Tom serves as Content Director for Healthegy, joining the company in 2014, to create and manage a new line of podcasts, publications and other editorial products. At Healthegy, Tom hosts the OIS Podcast and MedtechTalk, contributes to the Engage and Eye on Innovation newsletters and assists in the agenda development of new and existing conferences.

SUBSCRIBE TO OUR NEWSLETTER

Get The Latest News In Opthalmologic Innovation To Your Inbox.

We respect your privacy and will never send you spam.

Something went wrong. Please check your entries and try again.